NYSE:PFE

Pfizer Inc (PFE)

27.75
+0.03 (0.11%)
as of Sep 14, 2026, 5:42:20 pm Market Open.
583 watching
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY
Now is a good time for drug stocks.
BUY
At a good level now.
BUY
Earnings growth is sustainable.
BUY
In the midst of a large merger.
BUY
Extremely cheap. Great product line up.
WEAK BUY
Starting to look good at $26.
DON'T BUY
Great company. Could drop further.
BUY ON WEAKNESS
Good long term track record. Good management. Would like at a lower level.
BUY
Likes the drug sector.
BUY
Sector has been hit hard. At a good level. Prefers Pfizer over Merck.
DON'T BUY
DON'T BUY
Maney that went in as a defensive move is now leaving. Valuation in the sector got too high.
BUY
Excellent company. Should meet their growth potential this year. Great product lines.
WEAK BUY
Company has been doing well. Revenues growing @ 10%, earnings @ 20%. Trading at 19 X. Great long term.
DON'T BUY
Expensive.
Showing 811 to 825 of 890 entries